Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non–Small-Cell Lung Cancer A single-institutional ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that the latest results from its pivotal Phase 3 study of Multikine, a presurgical cancer immunotherapy, were ...
Histopathology analysis confirmed improved 5-year survival in Multikine-treated subjects, showed improved progression free survival and improved local regional control, and significantly lowered death ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback